2-(1H-benzimidazol-2-ylmethyl)benzene-1,4-diol, also known as **2-(1H-benzimidazol-2-ylmethyl)hydroquinone** or **BBH**, is a **small molecule** with a **complex structure** that combines a **benzimidazole** ring with a **hydroquinone** moiety.
**Structure:**
* **Benzimidazole ring:** A nitrogen-containing heterocyclic ring system, common in many bioactive molecules.
* **Hydroquinone:** A benzene ring with two hydroxyl groups (-OH), known for its antioxidant properties.
* **Linkage:** A methylene group (-CH2-) connects the benzimidazole and hydroquinone rings.
**Importance in Research:**
BBH is a molecule of interest in research due to its potential applications in various fields:
**1. Antioxidant Activity:**
* The hydroquinone group is known to scavenge free radicals, contributing to the antioxidant activity of BBH.
* This antioxidant potential has been investigated for its role in preventing oxidative stress and its potential for applications in treating diseases associated with oxidative damage.
**2. Antimicrobial Activity:**
* Benzimidazole derivatives are known to exhibit antimicrobial properties, targeting various bacterial and fungal species.
* BBH has shown promising activity against some bacterial strains, suggesting its potential as a lead compound for developing new antibiotics.
**3. Anti-Cancer Activity:**
* Some studies have investigated the potential of BBH as an anticancer agent.
* The benzimidazole ring structure can interact with DNA, potentially inhibiting cell proliferation and inducing apoptosis.
**4. Other Potential Applications:**
* BBH has also been explored for its potential in other areas, including:
* **Neuroprotection:** Its antioxidant properties might offer protection against neurodegenerative diseases.
* **Anti-inflammatory Activity:** BBH has shown some anti-inflammatory effects in preclinical studies.
**Key Points:**
* BBH is a complex molecule with potential biological activity.
* The combination of a benzimidazole and hydroquinone moiety contributes to its diverse biological actions.
* Research into BBH is ongoing to explore its full therapeutic potential in various disease areas.
**Further Research:**
* More in-depth studies are needed to understand the exact mechanisms of action of BBH and optimize its pharmacological properties for clinical applications.
* Further research is also required to evaluate its safety and efficacy in preclinical and clinical trials.
ID Source | ID |
---|---|
PubMed CID | 882243 |
CHEMBL ID | 1376835 |
CHEBI ID | 114796 |
SCHEMBL ID | 582154 |
Synonym |
---|
AKOS002162073 |
HMS2638N24 |
IFLAB1_004015 |
2-(1h-benzimidazol-2-ylmethyl)-1,4-benzenediol |
smr000298430 |
MLS000676416 , |
OPREA1_114011 |
OPREA1_021779 |
CHEBI:114796 |
HMS1423G11 |
2-(1h-benzimidazol-2-ylmethyl)benzene-1,4-diol |
STK965302 |
HMS3359I15 |
SCHEMBL582154 |
LGDLZQUSAVSGIM-UHFFFAOYSA-N |
2-(1h-benzoimidazol-2-ylmethyl)benzene-1,4-diol |
cid_882243 |
2-(1h-benzimidazol-2-ylmethyl)hydroquinone |
bdbm80714 |
CHEMBL1376835 |
Q27196201 |
SR-01000446440-1 |
sr-01000446440 |
Class | Description |
---|---|
benzimidazoles | An organic heterocyclic compound containing a benzene ring fused to an imidazole ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 10.0000 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 21.3313 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
WRN | Homo sapiens (human) | Potency | 55.3239 | 0.1683 | 31.2583 | 100.0000 | AID651768; AID720497 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 35.4813 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
TDP1 protein | Homo sapiens (human) | Potency | 18.6462 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 25.1189 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 6.3096 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 28.1838 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 3.1623 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 6.8061 | 0.5406 | 17.6392 | 96.1227 | AID720503 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 3.5481 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 2.5119 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 8.9125 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 39.8107 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 15.8489 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
hexokinase HKDC1 | Homo sapiens (human) | IC50 (µMol) | 5.2400 | 2.4900 | 7.7444 | 12.4000 | AID504729; AID504763 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |